Comparative Pharmacology
Head-to-head clinical analysis: IOBENGUANE I 123 versus PYLARIFY TRUVU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOBENGUANE I 123 versus PYLARIFY TRUVU.
IOBENGUANE I-123 vs PYLARIFY TRUVU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iobenguane I-123 is a radiopharmaceutical analog of norepinephrine that is taken up by adrenergic neurons and neuroendocrine tumors via the norepinephrine transporter (NET). It localizes in tissues rich in sympathetic innervation and tumors expressing NET, enabling scintigraphic imaging.
PYLARIFY is a PSMA-targeted PET imaging agent composed of a urea-based PSMA ligand (piflufolastat) labeled with fluorine-18. It binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells, allowing PET imaging for detection of PSMA-positive lesions.
Intravenous administration of 5 mCi (185 MBq) as a single dose for imaging.
1 mg/kg intravenously every 3 months.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours; clinically relevant for imaging timing (optimal scanning at 24 hours post-injection)
Terminal elimination half-life: approximately 77 hours (range 68-85 hours) in patients with prostate cancer. This supports a 2-week dosing interval for single-photon emission computed tomography (SPECT) imaging.
Renal: 40-60% as unchanged iobenguane within 24 hours; biliary/fecal: minimal (<5%)
Renal excretion: approximately 93% (3% unchanged, 97% as metabolites). Fecal excretion: approximately 5%. Biliary excretion is negligible.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical